Abstract
Minimal residual disease (MRD) status is the most relevant prognostic marker in multiple myeloma (MM). Recently, IMWG has incorporated MRD-negative status as a criterion to define stringent clinical response (sCR) using next-generation flow cytometry (NGF) i.e. high-sensitivity flow cytometry (HSFC). Herein, we present our experience in the standardization of HSFC and MRD monitoring in MM.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have